Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
Status:
Enrolling by invitation
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
EDG-5506-203 MESA is an open-label extension study to assess the long-term effect of
sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults and
adolescents with Becker muscular dystrophy